| Symbol
| JAM3
| contributors: shn/npt/pgu - updated : 24-08-2020
|
| HGNC name
| junctional adhesion molecule 3
|
| HGNC id
| 15532
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
|
significantly elevated in renal carcinoma cells compared with that in renal tubular epithelial cells  | |
Variant & Polymorphism
| 
| |
| Candidate gene
| is a new identification tool in B-cell lymphoma diagnosis |
| Marker
| can be used as a potential noninvasive biomarker for colorectal cancer (CRC) diagnosis |
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | hemopathy | | |
| Targeting JAM-C could thus constitute a new therapeutic strategy to prevent lymphoma cells from reaching supportive microenvironments not only in the bone marrow and lymph nodes but also in the spleen | | cancer | brain | | |
| potential of JAM3 and JAM2 as new targets for the treatment of human gliomas | | cancer | urinary | | |
| novel target gene for the diagnosis and treatment of renal cell carcinoma (RCC) | | immunology | infectious | | |
| reduction of the pro-inflammatory aged neutrophils by blockade of JAM3 has a novel therapeutic potential in sepsis-induced acute lung injury (ALI) |
| |
|
| JAM-C gene knocked out mice exhibited loss of integrity of the myelin sheath, defective nerve conduction and motor abnormalities | |
JAM3 knockdown caused a delay in the hfRPE cell polarization, and JAM3 inhibition significantly decreased the chemokine-induced transmigration of granulocytes through the hfRPE monolayer |